Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats

Journal of Applied Toxicology

Volumn 23, Issue 1, 2003, Pages 71-74

  Fadillioǧlu, Ersin ^a   Erdoǧan, Hasan ^a   Söǧüt, Sadik ^a   Kuku, Irfan ^a  

^a INONU UNIVERSITY   (Turkey)

Author keywords

Antioxidants; Cardiotoxicity; Catalase; Doxorubicin; Erdosteine; Glutathione peroxidase; Lipid peroxidation; Oxidants; Superoxide dismutase

Indexed keywords

CATALASE; DOXORUBICIN; ERDOSTEINE; GLUTATHIONE PEROXIDASE; MEMBRANE LIPID; MUCOLYTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; CARDIOMYOPATHY; CELL ORGANELLE; CONTROLLED STUDY; ENZYME ACTIVITY; HEART; HEART PROTECTION; LIPID PEROXIDATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CARDIOMYOPATHIES; CATALASE; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG THERAPY, COMBINATION; EXPECTORANTS; FATTY ACIDS; GLUTATHIONE PEROXIDASE; HEART; LIPID PEROXIDATION; MALE; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; THIOGLYCOLATES; THIOPHENES;

FELIS CATUS;

EID: 0347722762     PISSN: 0260437X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jat.889     Document Type: Review

References (26)

1. Abuja PM, Albertini R. 2001. Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins, Clin. Chim. Acta 306: 1-17.
2. Aebi H. 1974. Catalase. In Methods of Enzymatic Analysis, Bergmeyer HU (ed.). Academic Press: New York; 673-677.
3. Akimoto H, Bruno NA, Slate DL, Billingham ME, Torti SV, Torti FM. 1993. Effect of verapamil on doxorubicin cardiotoxicity: altered muscle gene expression in cultured neonatal rat cardiomyocytes. Cancer Res. 53: 4658-4664.
4. Arnhold J, Osipov AN, Spalteholz H, Panasenko OM, Schiller J. 2001. Effects of hypochlorous acid on unsaturated phosphatidylcholines. Free Radic. Biol. Med. 31: 1111-1119.
5. Braga PC, Sasso MD, Sala MT, Gianelle V. 1999. Effects of erdosteine and its metabolites on bacterial adhesiveness. Drug Res. 49: 344-350.
6. Braga PC, Sasso MD, Zuccotti T. 2000. Assessment of the antioxidant activity of the SH metabolite I of erdosteine on human neutrophil oxidative bursts, Drug Res. 50: 739-746.
7. Cassidy SC, Chan DP, Rowland DG, Allen HD. 1998. Effects of doxorubicin on diastolic function, contractile reserve, and ventricular-vascular coupling in piglets. Pediatr. Cardiol. 19: 450-457.
8. Dechant KL, Noble S. 1996. Erdosteine. Drug 52: 875-881.
9. Doroshow JH. 1983. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 43: 460-472.
10. Durak I, Yurtarslanl Z, Canbolat O, Akyol O. 1993. A methodological approach to superoxide dismutase (SOD) activity assay based on inhibition of nitroblue tetrazolium (NBT) reduction. Clin. Chim. Acta 214: 103-104.
11. Esterbauer H, Cheeseman KH. 1990. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. In Methods in Enzymology, vol. 186, Oxygen Radicals in Biological Systems, Packer L, Glazer AN (eds). Academic Press: California; 407-421.
12. Falcone G, Filippelli W, Mazzarella B, Tufano R, Mastronardi P, Filippelli A, Berrino L, Rossi F. 1998. Cardiotoxicity of doxorubicin: effects of 21-aminosteroids. Life Sci. 63: 1525-1532.
13. Gazzani G, Fregnan GB, Vandoni G. 1989. In vitro protection by erdosteine against oxidative inactivation of alpha-1-antitrypsin by cigarette smoke. Respiration 55: 113-118.
14. Herken H, Uz E, Ozyurt H, Sogut S, Virit O, Akyol O. 2001. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 6: 66-73.
15. Herman EH, Zhang J, Chadwick DP, Ferrans VJ. 2000. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother. Pharmacol. 45: 329-334.
16. Irmak MK, Koltuksuz U, Kutlu NO, Yagmurca M, Ozyurt H, Karaman A, Akyol O. 2001. The effect of caffeic acid phenethyl ester on ischemia-reperfusion injury in comparison with alpha-tocopherol in rat kidneys. Urol. Res. 29: 190-193.
17. Lowry O, Rosenbraugh N, Farr L, Rondall R. 1951. Protein measurement with the folin-phenol reagent. J. Biol. Chem. 183: 265-275.
18. Nazeyrollas P, Prevost A, Baccard N, Manot L, Devillier P, Millart H. 1999. Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity. Cancer Chemother. Pharmacol. 43: 227-232.
19. Olson RD, Mushlin PS. 1990. Doxorubicin cardiotoxicity analysis of prevailing hypotheses. FASEB J. 4: 3076-3086.
20. Paglia DE, Valentine WN. 1967. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 70: 158-170.
21. Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA. 2001. Cardioprotective effects of zofenopril, a new aniotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur. J. Pharmacol. 414: 71-78.
22. Saeki K, Obi I, Ogiku N, Shigekawa M, Imagawa T, Matsumoto T. 2002. Doxorubicin directly binds to the cardiac-type ryanodine receptor. Life Sci. 70: 2377-2389.
23. Shan K, Lincoff M, Young JB. 1996. Anthracycline-induced cardiotoxicity. Ann. Intern. Med. 125: 47-58.
24. Sun Y, Oberley LW, Li Y. 1988. A simple method for clinical assay of superoxide dismutase. Clin. Chem. 34: 497-500.
25. Venditti P, Balestrieri M, De Leo T, Di Meo S. 1998. Free radical involvement in doxorubucin-induced electrophysiological alterations in rat papillary muscle fibres. Cardiovasc. Res. 38: 695-702.
26. Zhou S, Palmeira CM, Wallace KB. 2001. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol. Lett. 121: 151-157.